

Biomarkers to manage severe asthma in clinical practice

Reference List

1. Australian Approved Product Information for DUPIXENT (dupilumab). 29 June 2022. [Click to access](#)
2. Australian Asthma Handbook V2.2, published April 2022. [Click to access](#). Accessed March 2023.
3. Australian Government. Department of Health and Aged Care. Medicare Benefits Schedule – Item 11507. [Click to access](#). Accessed March 2023.
4. Bafadhel M, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. *Lancet Respir Med*. 2018;6:117–126. [\[PMID: 29331313\]](#)
5. Beasley R, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. *N Engl J Med*. 2019;380:2020–2030. [\[PMID: 31112386\]](#)
6. Berry MA, et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. *Clin Exp Allergy*. 2005;35:1175–1179 [\[PMID: 16164444\]](#)
7. Pavord ID et al. (2022) B93 BREAKTHROUGHS IN PEDIATRIC AND ADULT ASTHMA CLINICAL TRIALS. p. A3418-A. [Click to access](#).
8. Castro M, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. *N Engl J Med*. 2018;378:2486–2496. [\[PMID: 29782217\]](#)
9. Couillard S, et al. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. *Thorax*. 2022;77:199–202. [\[PMID: 34362839\]](#)
10. Couillard S, et al. *Respirology*. 2022;27:573–577. Sub-stratification of type-2 high airway disease for therapeutic decision-making: A 'bomb' (blood eosinophils) meets 'magnet' (FeNO) framework. [\[PMID: 35591794\]](#)
11. Ducharme FM, et al. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. *Cochrane Database Syst Rev*. 2010(4):Cd005533. [\[PMID: 20393943\]](#)
12. Dutoit JI, et al. Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not. *Am Rev Respir Dis*. 1987;136(5):1174–1178. [\[PMID: 3674580\]](#)
13. Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. *Nat Rev Immunol*. 2015;15:57–65. [\[PMID: 25534623\]](#)
14. Fitzgerald JM, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. *Lancet Respir Med*. 2018;6:51–64. [\[PMID: 28919200\]](#)
15. Flood-Page P, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. *Am J Respir Crit Care Med*. 2007;176:1062–1071. [\[PMID 17872493\]](#)
16. Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. *Nat Rev Drug Discov*. 2016;15:35–50. [\[PMID: 26471366\]](#)
17. GINA. Global strategy for asthma management and prevention. 2022. [Click to access](#). Accessed March 2023.
18. Gov.UK. Health profile for England: 2017. [Click to access](#).
19. Haldar P, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. *N Engl J Med*. 2009;360:973–984. [\[PMID: 19264686\]](#)
20. Hammad H and Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. *Nat Rev Immunol*. 2008;8:193–204. [\[PMID: 18301423\]](#)
21. Hastie AT, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. *J Allergy Clin Immunol*. 2013;132:72–80. [\[PMID: 23706399\]](#)
22. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. *J Allergy Clin Immunol*. 2003;111:677–690; quiz 91. [\[PMID: 12704343\]](#)
23. Kaplan A, et al. Impact of comorbid conditions on asthmatic adults and children. *NPJ Prim Care Respir Med*. 2020;30:36. [\[PMID: 32820164\]](#)
24. Kerstjens, HAM et al. Captain Study: Simultaneous Step-Up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. *Am J Respir Crit Care Med* 2020;201:A4209. [Click to access](#).
25. Kraft M, et al. Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. *Eur Respir J*. 2021;58(6). [\[PMID: 34112734\]](#)
26. Laitinen LA, et al. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. *J Allergy Clin Immunol*. 1992;90:32–42. [\[PMID: 1629507\]](#)
27. Lee LA, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. *Lancet Respir Med*. 2021;9:69–84. [\[PMID: 32918892\]](#)
28. Malinovschi A, et al. Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity. *J Allergy Clin Immunol*. 2016;138:1301–1308. e2. [\[PMID: 27113848\]](#)
29. Masoli M, et al. Clinical dose-response relationship of fluticasone propionate in adults with asthma. *Thorax*. 2004;59:16–20. [\[PMID: 14694240\]](#)
30. Menzies-Gow A, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. *J Allergy Clin Immunol*. 2003;111:714–719. [\[PMID: 12704348\]](#)

31. Nonaka M, et al. Combined stimulation with Poly(I:C), TNF-alpha and Th2 cytokines induces TARC production by human fibroblasts from the nose, bronchioles and lungs. *Int Arch Allergy Immunol*. 2010;152:327–341. [\[PMID: 20185925\]](#)
32. O'Byrne PM, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. *N Engl J Med*. 2018;378:1865–1876. [\[PMID: 29768149\]](#)
33. Ortega HG, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. *Lancet Respir Med*. 2016;4:549–556. [\[PMID: 27177493\]](#)
34. Pavord ID and Agusti A. Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease. *Eur Respir J*. 2016;47:1299–1303. [\[PMID: 27132257\]](#)
35. Pavord ID, et al. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. *J Allergy Clin Immunol Pract*. 2022. Epub ahead of print: DOI: 10.1016/j.jaip.2022.11.043. [\[PMID: 36535524\]](#)
36. Pavord ID, et al. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. *J Allergy Clin Immunol Pract*. 2023;11(4):1213-1220.e2. [\[PMID: 36535524\]](#)
37. Pavord ID, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet*. 2012;380:651–659. [\[PMID: 22901886\]](#)
38. Pavord ID, et al. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. *Lancet Respir Med*. 2020;8:671–680. [\[PMID: 32171064\]](#)
39. Petsky HL, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. *Cochrane Database Syst Rev*. 2016;9:CD011440. [\[PMID: 27580628\]](#)
40. Petsky HL, et al. Exhaled nitric oxide levels to guide treatment for children with asthma. *Cochrane Database Syst Rev*. 2016;11:CD011439. [\[PMID: 27825189\]](#)
41. Price DB, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. *Lancet Respir Med*. 2015;3:849–858 [\[PMID: 26493938\]](#)
42. Rastogi S, et al. P198 FeNo and blood eosinophils as biomarkers in predicting asthma exacerbations. *Thorax*. 2017;72:A190.1. [Click to access.](#)
43. Reddel HK, et al. Optimal asthma control, starting with high doses of inhaled budesonide. *Eur Respir J*. 2000;16:226–235. [\[PMID: 10968496\]](#)
44. Robinson D, et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. *Clin Exp Allergy*. 2017;47:161–75. [\[PMID: 28036144\]](#)
45. Schneider A, et al. Diagnosing asthma in general practice with portable exhaled nitric oxide measurement – results of a prospective diagnostic study. *Respir Res*. 2009;10:15. [\[PMID: 19254389\]](#)
46. Schneider A, et al. Diagnostic accuracy of spirometry in primary care. *BMC Pulm Med*. 2009;9:31. [\[PMID: 26493938\]](#)
47. Shaw DE, et al. Balancing the needs of the many and the few: where next for adult asthma guidelines? *Lancet Respir Med*. 2021;9:786–794. [\[PMID: 33639099\]](#)
48. Shrimanker R, et al. Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis. *Am J Respir Crit Care Med*. 2019;200:1308–1312. [\[PMID: 31298922\]](#)
49. Sidhu SS, et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. *Proc Natl Acad Sci U S A*. 2010;107:14170–14175. [\[PMID: 20660732\]](#)
50. Sobieraj DM, et al. Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis. *JAMA*. 2018;319:1473–1484. [\[PMID: 29554174\]](#)
51. Southworth T, et al. Type-2 airway inflammation in mild asthma patients with high blood eosinophils and high fractional exhaled nitric oxide. *Clin Transl Sci*. 2021;14:1259–1264. [\[PMID: 34106513\]](#)
52. Suresh V, et al. Measurement of IL-13-induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells. *Am J Respir Cell Mol Biol*. 2007;37:97–104. [\[PMID: 17347445\]](#)
53. Wagener AH, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. *Thorax*. 2015;70:115–120. [\[PMID: 25422384\]](#)